EurekAlert! -
8 Dec 2013 07:00
(Dana-Farber Cancer Institute) Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.
Share this Article